Skip to main content
OpenTrials
Completed

NCT Number: NCT04462627

Reduction of COVID 19 Transmission to Health Care Professionals

When the COVID-19 virus infects a person, it enters the lung epithelial cells of its host and uses its genetic material to replicate.

The pulmonary epithelial cells of a part of the population, known as "secretors", are capable of expressing the antigens of the "ABO" system on their surface. This secretory status can be established by determining the antigens of the Lewis blood group system. When the virus replicates in an "secreting" individual, the antigens of the "ABO" system of the infected individual will be present on the surface of the viruses formed in his/her lungs.

It was shown in 2003 that the response of a given individual to the transmission of a virus depends on his/her blood group and on the antigens of the "ABO" system carried by the virus. A patient of group "O" would thus defend himself much better against a virus carrying antigens of blood group "A", the natural antibodies "anti-A" of the patient reducing the ability of the virus to bind to its specific receptor on pulmonary epithelial cells, to penetrate them to replicate itself. The first data collected in Wuhan (China) seems to confirm this hypothesis. A COVID-19 virus transmission model can therefore be established on the basis of blood groups.

In order to reduce the spread of the virus among nursing staff, it is possible to establish a preferential algorithm for patient management based on the "ABO" and "Lewis" blood groups of patients and "ABO" of nursing staff in health care units, if operational and human conditions allow.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID 19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Brugmann

Brussels, 1020, Belgium

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • COVID19 positive patients admitted within the CHU Brugmann Hospital

Exclusion criteria

  • None

Treatment and study plan

Blood group determination

Diagnostic Test

Determination of the blood group (ABO/LE)

Antibody titration

Diagnostic Test

Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.

Probiotic

Dietary Supplement

Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).

Primary outcomes

  1. Anti-A antibody concentration

    Time frame: baseline

    Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  2. Anti-A antibody concentration

    Time frame: Day 4

    Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  3. Anti-A antibody concentration

    Time frame: Week 1

    Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  4. Anti-A antibody concentration

    Time frame: Week 2

    Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  5. Anti-A antibody concentration

    Time frame: Week 3

    Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  6. Anti-B antibody concentration

    Time frame: baseline

    Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  7. Anti-B antibody concentration

    Time frame: Day 4

    Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  8. Anti-B antibody concentration

    Time frame: Week 1

    Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  9. Anti-B antibody concentration

    Time frame: Week 2

    Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  10. Anti-B antibody concentration

    Time frame: Week 3

    Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  11. Blood group

    Time frame: baseline

    Blood group (ABO/LE)

Sponsors and collaborators

Lead sponsor

Hanane EL KENZ

Other

Registry information

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Jul 8, 2020
Registry last updated
Jul 20, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.